SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

- Chinese FDA Approves SillaJen Trial in First-Ever Public Forum to Promote Transparency in Drug Approval Process -

Link address : http://www.prnewswire.com/news-releases/sillajen-and-lees-pharmaceutical-announce-approval-by-the-china-cfda-to-commence-phase-3-clinical-trial-for-oncolytic-immunotherapy-pexa-vec-in-liver-cancer-300492124.html